Clinical Trial Update: Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib in combination with gemcitabine for recurrent or metastatic nasopharyngeal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer | Phase 2 | Status: COMPLETED